Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial
Tóm tắt
To investigate the safety and efficacy of an early platelet function testing (PFT)-guided de-escalation of dual antiplatelet treatment (DAPT) in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with bioresorbable vascular scaffolds (BVS). Early DAPT de-escalation is a new non-inferior alternative to 12-months DAPT in patients with biomarker positive ACS treated with stent implantation. In this post-hoc analysis of the TROPICAL-ACS trial, which randomized 2610 ACS patients to a PFT-guided DAPT de-escalation (switch from prasugrel to clopidogrel) or to control group (uniform prasugrel), we compared clinical outcomes of patients (n = 151) who received a BVS during the index PCI. The frequency of the primary endpoint (cardiovascular death, myocardial infarction, stroke or BARC ≥ 2 bleeding) was 8.8% (n = 6) in the de-escalation group vs. 12.0% (n = 10) in the control group (HR 0.72, 95% CI 0.26–1.98, p = 0.52) at 12 months. One early definite stent thrombosis (ST) occurred in the control group (day 19) and 1 possible ST (sudden cardiovascular death) in the de-escalation group (day 86), both despite prasugrel treatment and in a background of high on-treatment platelet reactivity assessed at day 14 after randomization (ADP-induced platelet aggregation values of 108 U and 59 U, respectively). A PFT-guided DAPT de-escalation strategy could potentially be a safe and effective strategy in ACS patients with BVS implantation but the level of platelet inhibition may be of particular importance. This hypothesis-generating post-hoc analysis requires verification in larger studies with upcoming BVS platforms.
Tài liệu tham khảo
Sibbing D, Aradi D, Jacobshagen C et al (2016) A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Thromb Haemost 117:188–195. https://doi.org/10.1160/TH16-07-0557
Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390:1747–1757. https://doi.org/10.1016/S0140-6736(17)32155-4
Sibbing D, Gross L, Rieber J et al (2018) Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy332
Antman EM, Wiviott SD, Murphy SA et al (2008) Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 51:2028–2033. https://doi.org/10.1016/j.jacc.2008.04.002
Becker RC, Bassand J-P, Budaj A et al (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 32:2933–2944. https://doi.org/10.1093/eurheartj/ehr422
Velders MA, Abtan J, Angiolillo DJ et al (2016) Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 102:617–625. https://doi.org/10.1136/heartjnl-2015-308963
Serruys PW, Chevalier B, Sotomi Y et al (2016) Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 388:2479–2491. https://doi.org/10.1016/S0140-6736(16)32050-5
Capodanno D, Gori T, Nef H et al (2015) Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 10:1144–1153. https://doi.org/10.4244/EIJY14M07_11
Ali ZA, Gao R, Kimura T et al (2018) Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation 137:464–479. https://doi.org/10.1161/CIRCULATIONAHA.117.031843
Cassese S, Byrne RA, Jüni P et al (2018) Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention 13:1565–1573. https://doi.org/10.4244/EIJ-D-17-00492
Tello-Montoliu A, Rivera J, Hernández-Romero D et al (2016) Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. Platelets 27:777–783. https://doi.org/10.1080/09537104.2016.1184750
Ellis SG, Steffenino G, Kereiakes DJ et al (2017) Clinical, angiographic, and procedural correlates of acute, subacute, and late absorb scaffold thrombosis. JACC Cardiovasc Interv 10:1809–1815. https://doi.org/10.1016/j.jcin.2017.06.067
Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–260. https://doi.org/10.1093/eurheartj/ehx419
Neumann F-J, Ahlsson A, Alfonso F et al (2018) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 34:2949. https://doi.org/10.1093/eurheartj/ehy394
Cuisset T, Capodanno D (2018) Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice? EuroIntervention 14:19–23. https://doi.org/10.4244/EIJV14I1A2
Cassese S, Byrne RA, Ndrepepa G et al (2016) Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 387:537–544. https://doi.org/10.1016/S0140-6736(15)00979-4
Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762–1771. https://doi.org/10.1093/eurheartj/ehv104
Ormiston JA, Serruys PW, Regar E et al (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899–907. https://doi.org/10.1016/S0140-6736(08)60415-8
Onuma Y, Serruys PW, Perkins LEL et al (2010) Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122:2288–2300. https://doi.org/10.1161/CIRCULATIONAHA.109.921528
Katagiri Y, Stone GW, Onuma Y, Serruys PW (2017) State of the art: the inception, advent and future of fully bioresorbable scaffolds. EuroIntervention 13:734–750. https://doi.org/10.4244/EIJ-D-17-00499
Haude M, Ince H, Abizaid A et al (2016) Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J 37:2701–2709. https://doi.org/10.1093/eurheartj/ehw196
Abizaid A (2017) The FANTOM II study: first report for the 12-month clinical outcomes of the Fantom sirolimus eluting bioresorbable scaffold. EuroPCR, Sao Paulo
Abizaid A, Costa RA, Schofer J et al (2016) Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc Interv 9:565–574. https://doi.org/10.1016/j.jcin.2015.12.004
Haude M, Ince H, Kische S et al (2017) Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention 13:432–439. https://doi.org/10.4244/EIJ-D-17-00254
Cuisset T, Deharo P, Quilici J et al (2017) Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 38:3070–3078. https://doi.org/10.1093/eurheartj/ehx175